English, Ohio State University College of Arts and Sciences, Columbus, Ohio, USA.
Division of General Internal Medicine, Ohio State University College of Medicine, Columbus, Ohio, USA.
AJOB Empir Bioeth. 2024 Jul-Sep;15(3):214-225. doi: 10.1080/23294515.2023.2274606. Epub 2023 Nov 14.
Patients with chronic pain face significant barriers in finding clinicians to manage long-term opioid therapy (LTOT). For patients on LTOT, it is increasingly common to have them sign opioid treatment agreements (OTAs). OTAs enumerate the risks of opioids, as informed consent documents would, but also the requirements that patients must meet to receive LTOT. While there has been an ongoing scholarly discussion about the practical and ethical implications of OTA use in the abstract, little is known about how clinicians use them and if OTAs themselves modify clinician prescribing practices.
To determine how clinicians use OTAs and the potential impacts of OTAs on opioid prescribing.
We conducted qualitative analysis of four focus groups of clinicians from a large Midwestern academic medical center. Groups were organized according to self-identified prescribing patterns: two groups for clinicians who identified as prescribers of LTOT, and two who did not.
17 clinicians from General Internal Medicine, Family Medicine, and Palliative Care were recruited using purposive, convenience sampling.
Discussions were recorded, transcribed, and analyzed for themes using reflexive thematic analysis by a multidisciplinary team.
Our analysis identified three main themes: (1) OTAs did not influence clinicians' decisions whether to use LTOT generally but did shape clinical decision-making for individual patients; (2) clinicians feel OTAs intensify the power they have over patients, though this was not uniformly judged as harmful; (3) there is a potential misalignment between the intended purposes of OTAs and their implementation.
This study reveals a complicated relationship between OTAs and access to pain management. While OTAs seem not to impact the clinicians' decisions about whether to use LTOT generally, they do sometimes influence prescribing decisions for individual patients. Clinicians shared complex views about OTAs' purposes, which shows the need for more clarity about how OTAs could be used to promote shared decision-making, joint accountability, informed consent, and patient education.
慢性疼痛患者在寻找管理长期阿片类药物治疗(LTOT)的临床医生方面面临重大障碍。对于接受 LTOT 的患者,越来越常见的是让他们签署阿片类药物治疗协议(OTAs)。OTAs 列举了阿片类药物的风险,就像知情同意书一样,但也规定了患者必须满足的要求才能获得 LTOT。虽然关于 OTA 在实践和伦理方面的使用一直存在持续的学术讨论,但对于临床医生如何使用它们以及 OTA 本身是否会改变临床医生的处方实践知之甚少。
确定临床医生如何使用 OTA 以及 OTA 对阿片类药物处方的潜在影响。
我们对来自中西部一所大型学术医疗中心的四组临床医生进行了定性分析。这些组是根据自我认定的处方模式组织的:两组是 LTOT 的处方医生,两组不是。
通过有目的、方便的抽样,从普通内科、家庭医学和姑息治疗中招募了 17 名临床医生。
记录讨论,使用多学科团队的反思性主题分析对转录内容进行主题分析。
我们的分析确定了三个主要主题:(1)OTAs 通常不会影响临床医生是否使用 LTOT 的决定,但会影响对个别患者的临床决策;(2)临床医生认为 OTA 加强了他们对患者的权力,尽管这并不总是被认为是有害的;(3)OTAs 的预期目的与其实施之间存在潜在的不匹配。
这项研究揭示了 OTA 与获得疼痛管理之间的复杂关系。虽然 OTA 似乎不会影响临床医生是否普遍使用 LTOT 的决定,但它们有时会影响对个别患者的处方决策。临床医生对 OTA 的目的有复杂的看法,这表明需要更清楚地了解如何使用 OTA 来促进共同决策、共同责任、知情同意和患者教育。